Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

W.Y. Zhou



Author of

  • +

    P1.07 - Poster Session 1 - Surgery (ID 184)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Surgery
    • Presentations: 1
    • +

      P1.07-042 - Video-assisted thoracic surgery lobectomy for unexpected pathologic N2 non-small cell lung cancer (ID 3032)

      09:30 - 09:30  |  Author(s): W.Y. Zhou

      • Abstract

      Background
      This study was performed to assess early and late outcomes of patho-logic N2 disease unexpectedly detected in patients with non-small cell lung cancer undergoing video-assisted thoracic surgery (VATS) lobectomy for clinical stage I.

      Methods
      We retrospectively reviewed the clinical features of patients with unex-pected N2 non-small cell lung cancer and their early and late outcomes in the VATS lobectomy group versus the open thoracotomy lobectomy group.

      Results
      The overall survival time for all 358 patients was 33.26±0.90 months. The overall survival time for 117 cases in the VATS lobectomy group was 36.02±1.44 months. The overall survival time for 241 cases in the open thoracotomy lobectomy group was 31.92±1.14 months. The survival rates for patients in the VATS lobec-tomy group were 92.31%, 36.75%, 5.13% at one, three, and five years, respectively. The survival rates for patients in the open thoracotomy lobectomy group were 92.12%, 21.58%, 2.49% at one, three, and five years, respectively. A significant differ-ence was found between the two groups regarding this factor (X[2] =3.88 ,P = 0.049).

      Conclusion
      VATS lobectomy is feasible and safe to perform on patients with minimal N2 non-small cell lung cancer. Even if lymph node metastasis is unexpect-edly detected during surgery, with rigor ous preoperative evaluation and systematic lymph node dissection, there is no need to convert to open thoracotomy lobectomy.

  • +

    P2.05 - Poster Session 2 - Preclinical Models of Therapeutics/Imaging (ID 158)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P2.05-018 - Interferon-β efficiently inhibited endothelial progenitor cell-induced tumor angiogenesis (ID 3042)

      09:30 - 09:30  |  Author(s): W.Y. Zhou

      • Abstract

      Background
      Neovascularization has a critical role in the growth and metastatic spread of tumors, and involves recruitment of circulating endothelial progenitor cells (EPCs) from bone marrow. In this study, we examined whether EPCs could promote tumor angiogenesis, and found that the tumor growth was enhanced by the administration of EPCs.

      Methods
      To test the hypothesis that genetically modified bone marrow-derived EPCs can be effective carriers of therapeutic agents to tumor sites, we conducted human interferon-beta (HuIFN- b) gene transfection of EPCs with a virus vector in vitro .

      Results
      When HuIFN-b was applied in the ex vivo culture of EPCs, HuIFN- β-transduced EPCs achieved efficient killing of the total population of SPC-A1 cells, indicating a bystander effect was elicited by HuIFN- b-transduced EPCs in vitro . When SCP-A1 cancer cells were coimplanted along with ex vivo cultivated EPCs subcutaneous injection in nude mice, the tumor growth was increased. However, the anti-tumor effect of interferon-beta (IFN- β) offset the tumor-progressive character of EPCs and the tumor growth, and the vascular density of tumor tissues increased by coimplanted EPCs were decreased upon IFN- b treatment. In addition, overall expression levels of vascular endothelial growth factor in tumor tissues were decreased upon IFN-b treatment.

      Conclusion
      Our results suggest that gene-transfected EPCs could be useful as a tumor-specific drug delivery system.